BioVest International Announces Addition to Senior Management Team

October 19, 2005, Worcester, MA.

BioVest International today announced the promotion of Debora Jamieson to the newly created position of Vice President for Operations and Program Management. In her new role, Ms Jamieson will be responsible for planning and coordinating all vaccine manufacturing activities at the BioVest Worcester facility, and for ensuring effective interaction among the key functional areas within BioVest.

Dr. Carl M. Cohen, BioVest C.O.O. praised Ms. Jamieson’s considerable contributions to BioVest, “Deb was responsible for our having met all of the very aggressive manufacturing goals we established for the Worcester facility almost a year ago. This includes successfully bringing all vaccine activities from biopsy processing through sterile fill into our Worcester facility. Deb also created an effective project management structure that ensures that our vaccines are manufactured and released efficiently and on time. By this promotion we recognize her past contributions as well as the key role she will play in our future success as a major manufacturer of vaccine immunotherapetutics.”

Ms Jamieson joins a BioVest senior management team that also includes Dr. Abdellah Sentissi, Vice President of Quality Control and Quality Assurance, and Mr. David Aglow, Vice President of Manufacturing.

About BioVest International: BioVest International is a pioneer in the development of advanced individualized immunotherapies for life threatening cancers of the blood system. BioVest has a deep foundation in the manufacture of biologics for research and for clinical trials. In addition, BioVest develops, manufactures, and markets patented cell culture systems and equipment to pharmaceutical, diagnostic and biotechnology companies, as well as leading research institutions worldwide, including the new AutovaxTM automated vaccine manufacturing instruments. BioVest’s therapy for Follicular non-Hodgkin’s lymphoma is currently in a phase 3 pivotal clinical trial at 25 major centers in the US. and is being conducted under a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute.